SCHEMBL4156366

SCHEMBL4156366

Cn1c(CCl)nc2c(Cl)cccc21

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HSP90AB1 P08238 1/20 0.39
SMN1; SMN2 Q16637 3/20 0.38
PSMB8 P28062 1/20 0.37
TP53 P04637 2/20 0.37
PRMT5 O14744 1/20 0.37
NPC1 O15118 4/20 0.36
RAB9A P51151 4/20 0.36
MAPT P10636 2/20 0.36
LMNA P02545 2/20 0.36
PPARG P37231 1/20 0.36
MAPK1 P28482 1/20 0.36
GRM2 Q14416 1/20 0.36
PKM P14618 1/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
CYP11B2 P19099 1/20 0.34
HTR3A P46098 1/20 0.34
PDE10A Q9Y233 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11923731 0.86 DPP4 (0.41) HSP90AB1SMN1; SMN2PSMB8TP53PRMT5
SCHEMBL12362580 0.83 HSP90AB1 (0.49) HSP90AB1SMN1; SMN2NPC1RAB9AMAPT
SCHEMBL12362614 0.82 DPP4 (0.44) SMN1; SMN2TP53NPC1RAB9ALMNA
SCHEMBL4726673 0.81 GRM2 (0.37) SMN1; SMN2TP53NPC1RAB9AMAPT
SCHEMBL7894744 0.81 GRM2 (0.43) NPC1RAB9APPARGGRM2MEN1
SCHEMBL16790525 0.81 MEN1 (0.36) HSP90AB1SMN1; SMN2PSMB8TP53PRMT5
SCHEMBL1161432 0.79 RAB9A (0.50) HSP90AB1RAB9ALMNAMAPK1GRM2
SCHEMBL1161593 0.78 GRM2 (0.39) SMN1; SMN2PSMB8NPC1RAB9AMAPT
SCHEMBL3295739 0.77 CYP1A2 (0.49) SMN1; SMN2PSMB8PRMT5NPC1RAB9A
SCHEMBL31050086 0.76 FGFR1 (0.42) SMN1; SMN2PSMB8PRMT5PPARGMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090192169-A1 Bicyclic Benzimidazole Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators ASTRAZENECA AB (SE) 2009-07-30 US disclosed
US-20090192169-A1 Bicyclic Benzimidazole Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators ASTRAZENECA AB (SE) 2009-07-30 US disclosed
US-20090192169-A1 Bicyclic Benzimidazole Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators ASTRAZENECA AB (SE) 2009-07-30 US disclosed
WO-2007115077-A2 BICYCLIC BENZIMIDAZOLE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS ASTRAZENECA AB (SE) 2007-10-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090192169-A1 Bicyclic Benzimidazole Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators GRM1, GRIN1, GRM2 HSP90AB1 4072/4885SMN1; SMN2 3250/4885PSMB8 2856/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.